Timothy Williams
Known title: SVP & General CounselCIK: 0001748392
Associated companies
Transaction History
| VNDA | ▼ Sell | Open Market | 42,434 | $351K | 3/2/2026 | View on chart |
| VNDA | ▲ Buy | Grant | 125,000 | $0 | 2/18/2026 | View on chart |
| VNDA | ▼ Sell | Tax Withholding | 26,941 | $128K | 3/1/2025 | View on chart |
| VNDA | ▲ Buy | Grant | 125,000 | $0 | 2/18/2025 | View on chart |
| VNDA | ▼ Sell | Open Market | 8,941 | $37K | 3/5/2024 | View on chart |
| VNDA | ▼ Sell | Open Market | 8,147 | $36K | 3/4/2024 | View on chart |
| VNDA | ▲ Buy | Grant | 125,000 | $0 | 2/16/2024 | View on chart |
| VNDA | ▼ Sell | Open Market | 14,600 | $96K | 6/13/2023 | View on chart |
| VNDA | ▼ Sell | Open Market | 8,301 | $52K | 3/3/2023 | View on chart |
| VNDA | ▼ Sell | Open Market | 8,437 | $53K | 3/2/2023 | View on chart |
| VNDA | ▲ Buy | Grant | 32,700 | $0 | 2/16/2023 | View on chart |
| VNDA | ▼ Sell | Open Market | 8,000 | $56K | 12/15/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 3,689 | $38K | 8/15/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 4,611 | $47K | 8/15/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 12,060 | $134K | 3/2/2022 | View on chart |
| VNDA | ▲ Buy | Grant | 32,700 | $0 | 2/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.